NDC 0338-0126
Myxredlin 1.00 [iU] per 1 mL injection, solution
On the label: Baxter Healthcare Corporation.
Where it's made
| Factory | Where | Role | Last FDA inspection |
|---|---|---|---|
| Baxter Healthcare Corporation | Round Lake, IL, United States | Makes it, tests it, packages it, labels it and sterilizes it | Serious problems, FDA actionApr 2, 2026 · 15 inspections, 2 with FDA action |
Recalls
- Aug 6, 2026 · Class II · Baxter Healthcare Corporation
CGMP Deviations
Lots: Lot # NC188630, NC188708, NC188791, NC188845, NC188876, NC188968, Exp Date: 12/31/2027; Lot # NC193719, NC193849, Exp Date: 04/30/2028; Lot # NC194051, NC194105, Exp Date: 05/31/2028; Lot # NC195171, Exp Date: 06/30/2028.
Class I recalls are the most serious; Class III the least. A recall covers specific lots, listed on each recall.
Product details
- Generic drug
- Insulin Human: every company that makes it
- Form
- injection, solution, intravenous
- Strength
- 1.00 [iU] per 1 mL
- Approval
- BLA BLA208157
- On the market since
- Jul 12, 2019
- Package NDCs
0338-0126-12- Official label
- DailyMed (National Library of Medicine), updated Mar 7, 2025
Got it by mail or from a pharmacy you don't know? Look the pharmacy up on Who Filled My Rx?